https://orcid.org/0000-0003-2159-0049
References
- Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics–2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492.
- Centers for Disease Control and Prevention. Atrial fibrillation fact sheet 2017; [May 4, 2018]. Available from: https://www.cdc.gov/dhdsp/data_statistics/.
- Fitch K, Broulette J, Kwong WJ. The economic burden of ischemic stroke and major hemorrhage in Medicare beneficiaries with nonvalvular atrial fibrillation: a retrospective claims analysis. Am Health Drug Benefits. 2014;7(4):200–209.
- Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4(3):313–320.
- Rost NS, Bottle A, Lee JM, et al. Stroke severity is a crucial predictor of outcome: an international prospective validation study. J Am Heart Assoc. 2016;5(1):e002433.
- Fonarow GC, Saver JL, Smith EE, et al. Relationship of National Institutes of Health Stroke Scale to 30-day mortality in Medicare beneficiaries with acute ischemic stroke. J Am Heart Assoc. 2012;1(1):42–50.
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891.
- Lip GY, Frison L, Halperin JL, et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41(12):2731–2738.
- Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100.
- Kogan E, Twyman K, Heap J, et al. Assessing stroke severity using electronic health record data: a machine learning approach. BMC Med Inform Decis Mak. 2020;20(1):8.
- Kogan E, Sjoeland E, Milentijevic D, et al. Validation of a machine learning approach to determine stroke severity of patients diagnosed with stroke in claims data. Stroke. 2020;51(suppl 1):ATP307.
- Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11(4):315–322.
- Harrington AR, Armstrong EP, Nolan PE Jr, et al. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44(6):1676–1681.
- Lee S, Anglade MW, Pham D, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012;110(6):845–851.
- Laliberte F, Cloutier M, Crivera C, et al. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users. Adv Ther. 2015;32(3):216–227.
- Alberts M, Chen YW, Lin JH, et al. Risks of stroke and mortality in atrial fibrillation patients treated with rivaroxaban and warfarin. Stroke. 2020;51(2):549–555.
- Sung SF, Hsieh CY, Kao Yang YH, et al. Developing a stroke severity index based on administrative data was feasible using data mining techniques. J Clin Epidemiol. 2015;68(11):1292–1300.
- Hung LC, Sung SF, Hsieh CY, et al. Validation of a novel claims-based stroke severity index in patients with intracerebral hemorrhage. J Epidemiol. 2017;27(1):24–29.
- Rozjabek HM, Coleman CI, Ashton V, et al. Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants. J Med Econ. 2019;22(8):751–759.
- Villines TC, Peacock WF. Safety of direct oral anticoagulants: insights from postmarketing studies. Am J Med. 2016;129(11S):S41–S46.